



Fred Hutch
Cancer Center

15th Annual Hematology and Oncology Review Course

(On-Demand)

December 4, 2024 – November 30, 2025

Enduring Material

UW Medicine

Course Syllabus

Table of Contents

	Page
Course Information.....	3
CME Accreditation.....	3
Access Instructions.....	4
Faculty Disclosure Summary.....	5-7
Credit Tracking Sheet	8
Notes Pages.....	9-20



Scan the QR code

Subscribe to our e-newsletter to learn about future education opportunities from Fred Hutchinson Cancer Center.

fredhutch.org/provider-blog

Course Information

COURSE DESCRIPTION

Join our renowned experts from Fred Hutchinson Cancer Center and the University of Washington School of Medicine for the 15th Annual Comprehensive Hematology and Oncology Review Course. This program includes 54 talks covering medical oncology and hematology standard-of-care updates, as well as talks reviewing integrative medicine, infectious disease complications, a multi-disease talk on radiation oncology, and benign white cell disorders. The lectures review data that inform current guidelines, recommendations, and recent advances regarding therapeutic options for patients with solid tumors and malignant and benign hematologic disorders. After completing the course, learners will have a deeper understanding of the pathogenesis, diagnostic evaluation, and therapeutic modalities available for a breadth of solid tumors and hematologic disorders.

COURSE OBJECTIVES

Upon completion of this activity, attendees should be able to:

- Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common malignant hematological diseases.
- Explain the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common solid tumor malignancies.
- Integrate guideline-based treatments into clinical practice while personalizing care appropriately for the patient.
- Organize new therapeutic and diagnostic approaches into clinical practice as appropriate.

TARGET AUDIENCE

This educational program is intended for physicians, advanced practice providers, nurses, pharmacists, residents and fellows interested in a comprehensive update on solid tumors and hematologic disorders, and will be of interest to those certifying or re-certifying for their boards.

ACCREDITATION (December 4, 2024 – November 30, 2025)

Accreditation with Commendation

The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation


The University of Washington School of Medicine designates this enduring material for a maximum of 35.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME CREDIT AND CERTIFICATES

In order to receive Continuing Medical Education credit (*AMA PRA Category 1 Credits™*) or a Certificate of Attendance, completion of the electronic evaluation and attendance attestation is required and is located under the first module. This process must be completed prior to the end of the accreditation term (November 30, 2025). Certificates can then be accessed by going to myCME→ Evaluations & Certificates.

Syllabus Access

Registration to this course grants online access to the conference syllabus materials from the UW CME website. Please visit www.uwcme.org. Click on “Sign In” and log in using your email and password.



Click on the following URL: <https://uw.cloud-cme.com/EN2502>

EN2502 - EN2502: Comprehensive Hematology and Oncology Review Course



- To access the content, elect “Tests.” All PDF and video content is available, grouped by modules. You can watch them as often as you would like through November 30, 2025.
- When accessing the PDF of the presentations, you will need to click the back arrow to return to the main course page and/or click the URL.
- Please do not complete the CME Attestation and Evaluation selection until you are sure you are done watching content for credit.

METHOD OF PARTICIPATION

Access to the internet is required. Each talk will have its associated presentation, recording and supplemental questions located in the Q&A document. Please make sure to review all three as part of the learning process. Completion of the credit attestation and evaluation are required in order to receive CME credit. This should be done at the conclusion of your learning and should be tracked using the included tracking sheet.

COPYRIGHT

The content is the property of the University of Washington and is protected by law, including but not limited to copyright and trademark statutes. This content is for educational purposes only and may not be used for commercial gain. The University of Washington reserves the right to revise or withdraw content from use. Redistribution of this content is strictly prohibited. For questions related to content use, please contact the CME office at cme@uw.edu.

Technical Assistance: If you need assistance accessing your account, or navigating the online system, please contact UW CME at cme@uw.edu.

Minimum Browser Requirements

Chrome version 70.0 or newer | Firefox version 63.0 or newer
 Internet Explorer version 11.0 or newer | Safari version 12.0 or newer

DISCLOSURE INFORMATION

The University of Washington School of Medicine requires any person in control of content disclose any financial relationships with ineligible companies whose products or services are discussed in educational presentations. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The ACCME defines an ineligible company as a company “*whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*”

The University of Washington School of Medicine is required to “mitigate” any conflicts prior to the educational program. Therefore, in light of the relationships/affiliations designated, each person in control of content has attested that:

- recommendations for patient care are based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options;
- all scientific research referred to, reported, or used in this educational activity in support or justification of a patient care recommendation conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation;
- new and evolving topics for which there is a lower (or absent) evidence base are clearly identified as such;
- content avoids advocating for, or promoting, practices that are not, or not yet, adequately based on current science, evidence, and clinical reasoning;
- content excludes any advocacy for, or promotion of, unscientific approaches to diagnosis or therapy, or recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

All relevant financial relationships listed have been mitigated.

<u>Faculty</u>	<u>Description of Relationship</u>
Christina Baik	Grant/Research support: Daiichi Sankyo, Inc., Nuvalent, AbbVie, Bristol-Myers Squibb Comp (BMS), AstraZeneca, Lilly, Pfizer, Janssen, Boehringer Ingelheim Pharmaceuticals, Inc.
Kalyan Banda	Grant/Research support: Lilly, Regeneron Pharmaceuticals, Inc., MorphoSys, Kineta
Shailender Bhatia	Grant/Research support: Incyte Corporation
Ryan Cassaday (planner, speaker)	Grant/Research support: Amgen, Inc., Incyte Corporation, Pfizer, Servier Advisory committees and/or review panels: Autolus and PeproMene Bio
Andrew Coveler (planner, speaker)	Grant/Research support: Taiho Pharmaceutical, AstraZeneca, Seagen, Nucana
Andrew Cowan	Grants/Research support: Janssen, Bristol-Myers Squibb Comp (BMS), Sanofi S.A., Regeneron Pharmaceuticals, Inc., Caelum, AbbVie. Consulting, speaking and/or teaching: HopeAI
Lee Cranmer	Grants/Research support: Merck, Exelixis, Inc., Eli Lilly, Philogen, Gradalis, Tracon, AADI Biosciences, Inhibrx Consulting, speaking and/or teaching: AADI Biosciences, Deciphera, Avacta Royalties or Patent Beneficiary: AADI Biosciences

Rafael Santana-Davila	Grants/Research support: ISA pharmaceuticals, Daiichi Sankyo, Inc., BeiGene, Merck, Pfizer, ALX oncology, AbbVie, Astellas, Jounce, Alpine, Monterosa Honoraria: Mirati Therapeutics, Genentech/Roche, Catalyst Pharmaceuticals, Amgen, Fosun Pharma, Boehringer Ingelheim, Daiichi Sankyo Consulting/Advisory: Mirati Therapeutics, Genentech/Roche, Catalyst Pharmaceuticals, Amgen, Fosun Pharma, Boehringer=Ingelheim, Daichi Sanko
Mengyang Di	Grants/Research support: BeiGene, Schrodinger Consulting, speaking and/or teaching: Genentech
Kleber Fertrin	Advisory committees and/or review panels : Bluebird Bio, Agios Pharmaceuticals Honoraria: Agios Pharmaceuticals Consulting, speaking and/or teaching: Agios Pharmaceuticals, Sanofi S.A.
David Garcia	Grants/Research support: Abbott
Solomon Graf	Grants/Research support: Janssen, Lilly, BeiGene, Genentech, AstraZeneca
William Gwin	Advisory committees and/or review panels: AstraZeneca, Gilead Science, Inc
Anna Halpern	Grants/Research support: Merck, PharmEssentia, Protagonist, Disc Medicine, Karyopharm Therapeutics, Gilead Sciences, Inc., Jazz Pharmaceuticals, Inc., Incyte Corporation Consulting Fee: Karyopharm Therapeutics
William Harris	Advisory committees and/or review panels: Boston Scientific Corporation Grant/Research support: AstraZeneca
Jessica Hawley	Grants/Research support: AstraZeneca, Bristol-Myers Squibb Comp (BMS), Barinthus, MacroGenics, Janssen, Amgen, Inc., Promicell Consulting, speaking and/or teaching: GlaxoSmithKline (GSK)
Gentry King	Advisory committees and/or review panels: AstraZeneca
Rebecca Kruse-Jarres	Advisory committees and/or review panels: Genentech, Roche Grant/Research support: Pfizer, Genentech
Sandhya Panch	Honoraria: Sanofi S.A. Consulting, speaking and/or teaching: Sobi
Mary-Elizabeth Percival	Grants/Research support: Pfizer, AbbVie, Celgene Corporation, Ascentage, Astex, Glycomimetics, Biosight
Christina Poh	Grants/Research support: Incyte, Dren Bio, Astex, Pfizer Consulting, speaking and/or teaching: Acrotech, Beigene, Seagen, Ipsen
Cristina Rodriguez	Grants/Research support: Merck ,Bristol-Myers Squibb Comp (BMS), AstraZeneca, Cue Biopharma, Ayala, Kura, Prelude Therapeutics, Sanofi S.A., Coherus, Seagen
Rachael Safyan	Grants/Research support: Exelixis, Verastem, Replimune.
Michael Schweizer	Grants/Research support: Pfizer, Novartis Corporation Pharmaceuticals, Zenith Epigenetics, Bristol-Myers Squibb Comp (BMS), Merck, Epigenetix, Xencor, Ambrx Advisory committees and/or review panels: Pfizer
Bart Scott	Consulting, speaking and/or teaching: Bristol-Myers Squibb Comp (BMS), Apellis

	Advisory committees and/or review panels: Incyte Corporation, Alexion Pharmaceuticals
Mazyar Shadman	Grants/Research support: AbbVie, AstraZeneca, BeiGene, Genentech, Genmab, Monopar, Mustang Bio, Vincerx. Consulting, speaking and/or teaching: AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb Comp (BMS), Lilly, Fate Therapeutics, Genentech, Genmab, Janssen, Kite Pharma, Merck, MorphoSys, Nurix Stocks or stock options, excluding diversified mutual funds: Koi Biotherapeutics
Veena Shankaran	Grants/Research support: Arcus Biosciences, Astellas.
Scott Tykodi	Grants/Research support: Bristol-Myers Squibb Comp (BMS), Pfizer, Exelixis, Iovance Biotherapeutics, Nektar Therapeutics, Merck, AVEO Oncology, Xencor, HiberCell
Vyshak Venur	Grants/Research support: Mimivax, Novocure, Chimerix, Servier, Ono Therapeutics
Rachel Yung	Grants/Research support: Pfizer
David Zhen	Grants/Research support: A2 Biotherapeutics, Bristol-Myers Squibb Comp (BMS), Cornerstone Pharmaceuticals, Legend Biotech, AstraZeneca, Daiichi Sankyo, Inc., Medigene, Merck, Pfizer, Lilly, Genentech Consulting, speaking and/or teaching: Boehringer Ingelheim Pharmaceuticals, Jazz Pharmaceuticals Inc., Exelixis, Inc., Legend Biotech, Medigene.

The following speaker(s)/reviewer(s) have indicated they do not have any relationships to disclose:

Ali, Naveed
 Appelbaum, Jacob
 Burwick, Nick
 Celentano, Isabelle (Reviewer)
 Cerminara, Zak
 Chen, Jonathan
 Cohen, Stacey
 Culberson, Alana (Reviewer)
 Eaton, Keith
 Fane, Meredith (Reviewer)
 Fogh, Shannon
 Giustini, Nicholas
 Hasan, Rida
 Hegerova, Livia

Herbord, Kristie (Reviewer)
 Horwitz, Marshall
 Hunter, Natasha
 Indorf, Amy
 Kwok, Mary
 Pagano, Monica
 Portuguese, Andrew
 Purcell, Tom (Reviewer)
 Shriyan, Ritu (Reviewer)
 Urban, Renata
 Vishnu, Prakash
 Yezefski, Todd
 Zamora, Danniell

✓	Topic	Section	Credits
	Adjuvant Therapy for Breast Cancer	Breast Oncology	0.75
	Metastatic Breast Cancer	Breast Oncology	0.75
	Therapy for Non-Invasive Breast Cancer	Breast Oncology	0.75
	Anal Cancer	GI Oncology	0.25
	Cholangiocarcinoma	GI Oncology	0.50
	Colorectal Cancer	GI Oncology	1.00
	Esophageal/Gastric Cancer	GI Oncology	0.75
	Gastrointestinal Neuroendocrine Tumors	GI Oncology	0.50
	Hepatocellular Cancer	GI Oncology	0.50
	Pancreatic Cancer	GI Oncology	0.50
	Bladder Cancer	GU Oncology	0.75
	Prostate Cancer	GU Oncology	1.00
	Renal Cell Carcinoma	GU Oncology	0.75
	Testicular Cancer	GU Oncology	0.75
	Benign White Cell Disorders	Hematology	0.75
	Bleeding Disorders	Hematology	0.75
	Consultative Hematology	Hematology	0.50
	Hematopoietic Cell Transplantation	Hematology	0.75
	Inherited & Acquired Marrow Failure	Hematology	0.50
	Iron Metabolism Disorders & Hemolytic Anemias	Hematology	0.50
	Myelodysplastic Syndromes	Hematology	0.50
	Myeloproliferative Neoplasms	Hematology	0.50
	Thalassemia & Hemoglobinopathies	Hematology	0.75
	Thrombocytopenia	Hematology	1.00
	Thrombosis & Anticoagulation	Hematology	0.75
	Transfusion Medicine	Hematology	0.75
	Acute Lymphoblastic Leukemia	Leukemia and Myelomas	0.50
	Acute Myeloid Leukemia	Leukemia and Myelomas	0.75
	Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) & Hairy Cell Leukemia	Leukemia and Myelomas	1.00
	Chronic Myeloid Leukemia	Leukemia and Myelomas	0.50
	Newly Diagnosed Myeloma	Leukemia and Myelomas	0.50
	Relapsed/Refractory Myeloma & Amyloidosis	Leukemia and Myelomas	0.75
	Smoldering Myeloma & MGUS	Leukemia and Myelomas	0.50
	B-NHL, Aggressive Non-Hodgkin Lymphoma	Lymphomas	0.75
	B-NHL, Indolent Non-Hodgkin Lymphoma	Lymphomas	0.75
	Hodgkin Lymphoma	Lymphomas	0.50
	T-Cell Lymphoma - NHL	Lymphomas	0.50
	CNS Cancers	Other Malignancies	0.75
	Gynecologic Oncology - Cervical and Endometrial Cancers	Other Malignancies	0.75
	Gynecologic Oncology - Ovarian Cancer	Other Malignancies	0.50
	Melanoma and other Skin Cancers	Other Malignancies	0.75
	Sarcoma	Other Malignancies	0.75
	Familial Syndromes	Supportive Care & Associated Specialties	0.75
	Hematology Pharmacology Pearls	Supportive Care & Associated Specialties	1.00
	Infectious Disease Complications	Supportive Care & Associated Specialties	0.75
	Integrative Medicine	Supportive Care & Associated Specialties	0.50
	Radiation Oncology - Multi-Disciplinary	Supportive Care & Associated Specialties	0.75
	Solid Tumor Pharmacology Pearls	Supportive Care & Associated Specialties	0.75
	Supportive Care	Supportive Care & Associated Specialties	0.75
	Head, Neck and Thyroid Cancer	Thoracic, Head and Neck	0.75
	Mesothelioma	Thoracic, Head and Neck	0.25
	Non-Small Cell Lung Cancer - Adjuvant/Locally Advanced	Thoracic, Head and Neck	0.75
	Non-Small Cell Lung Cancer - Metastatic	Thoracic, Head and Neck	0.50
	Small Cell Lung Cancer	Thoracic, Head and Neck	0.25
TOTAL (MAX 35.75)			

NOTES

[illegible]

[illegible]

NOTES

[illegible]

NOTES

This image shows a single page of white paper with horizontal blue lines. The lines are evenly spaced and run across the width of the page, typical of notebook paper or a document template. There are no margins, text, or other markings on the page.

This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

[illegible]

NOTES

[illegible]

NOTES

[illegible]

NOTES

[illegible]

This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

NOTES

This image shows a full page of blank, lined paper. It features approximately 20 horizontal blue lines spaced evenly across the page, typical of notebook or legal stationery. The lines are thin and light blue, set against a plain white background. There are no margins, text, or other markings present.

NOTES

This image shows a full page of blank, lined paper. It features approximately 20 evenly spaced horizontal blue lines across its entire width. The lines are thin and consistent in color, set against a plain white background. There are no margins, text, or other markings present on the page.